Monograph
G04CB02 - Dutasteride |
Propably not porphyrinogenic |
PNP |
Rationale
Dutasteride is not a substrate, inhibitor or inducer of CYP450 enzymes and no pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Oxosteroide
Therapeutic characteristics
Dutasteride is a testosterone 5-alpha-reductase inhibitor used in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
It is administered orally.
Metabolism and pharmacokinetics
Dutasteride is metabolized by CYP3A4/5 (SPC). Dutasteride and its metabolites are mainly excreted in the feaces (SPC).
Dutasteride does not have an effect on warfarin or digoxin and is thus not an inhibitor or inducer of CYP2C9 (SPC). In vitro interaction studies report that it is not an inhibitor of CYP1A2, 2A6, 2E1, 2C8, 2D6, 2C9, 2C19, 2B6 or 3A4 (SPC). No drug-drug interactions with dutasteride as perpetrator have been reported in the literature (Lexi-Interact, Keam 2008).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Dutasteride: a review of its use in the management of prostate disorders.
Keam SJ, Scott LJ. Drugs. 2008;68(4):463-85. |
18318566 |
| * | Government bodies | |
| 2. |
|
|
| * | Drug interaction databases | |
| 3. | Lexi-Interact in UpToDate. Dutasteride: Drug interaction program.
|
|
| * | Summary of Product Characteristics | |
| 4. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Avodart).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024